After-Hours Stock Movers 09/07: (RPRX) (JUNO) (ABEO) Higher; (GEVO) (TSCO) (PIR) Lower (more...)
- Target (TGT) November/December Comps Fell 1.3%; Lowers Guidance
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Today's After-Hours Movers
Repros Therapeutics Inc. (Nasdaq: RPRX) 43.9% HIGHER; provided posotive results of the first course of treatment from Repros ongoing study of Proellex® for the treatment of premenopausal women with confirmed symptomatic endometriosis.
Gevo, Inc. (Nasdaq: GEVO) 17.2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, Series E units, with each Series E unit consisting of one share of common stock and Series I warrants to purchase a certain number of shares of common stock. The Company is also offering Series F units, in lieu of Series E units, to those purchasers whose purchase of additional Series E units in the offering would result in the purchaser beneficially owning more than 4.99% of Gevos outstanding common stock following the completion of the offering. The Series F units will consist of pre-funded warrants to purchase one share of common stock and Series I warrants to purchase a certain number of shares of common stock. The units are to be sold by Gevo subject to market and other conditions in an underwritten public offering.
Netlist, Inc. (NASDAQ: NLST) 12.9% LOWER; announced a proposed $15 million underwritten public offering of its common stock, subject to market and other conditions. In addition, the Company intends to grant the underwriters an option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the offering.
Tractor Supply Company (NASDAQ: TSCO) 9.2% LOWER; provided a business update for the third quarter-to-date. Net sales for the third quarter are expected to increase approximately 4.2% to 5.0% to $1.54 billion to $1.55 billion from $1.48 billion in the third quarter of 2015, with comparable store sales ranging from flat to a decrease of (1.0)% versus an increase of 2.9% in last year's third quarter. The consensus is $1.61 billion. Given the lower sales, the Company expects net income per diluted share for the third quarter to be in the range of $0.65 to $0.67. **** versus the consensus of $0.72.
Pier 1 Imports, Inc. (NYSE: PIR) 8.3% LOWER; announced preliminary sales and earnings per share data for the second quarter ended August 27, 2016. Net sales for the second quarter decreased by approximately 6.7% compared to the same period a year ago. E-Commerce sales represented approximately 20% of net sales in the second quarter. Company comparable sales, which include e-Commerce, decreased approximately 4.3% compared to the same period a year ago. Second quarter loss per share is expected to be in the range of ($0.06) to ($0.05), excluding one-time items, if any, related to the planned departure of the Companys Chief Executive Officer, which was announced separately today. *** The Street sees Q2 revenue of $424.4 million and loss of $0.03 per share.
Mitcham Industries (NASDAQ: MIND) 7.4% LOWER; reported Q2 EPS of ($0.80), $0.31 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $11.2 million.
Juno Therapeutics (NASDAQ: JUNO) 6.4% HIGHER; In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patients own immune cells that are then genetically engineered to better identify and kill cancer cells.
Guidewire Software (NYSE: GWRE) 5.9% LOWER; reported Q4 EPS of $0.39, $0.07 better than the analyst estimate of $0.32. Revenue for the quarter came in at $141.18 million versus the consensus estimate of $136.09 million. GUIDANCE: Guidewire Software sees Q1 2017 EPS of ($0.07)-($0.04), versus the consensus of $0.07. Guidewire Software sees Q1 2017 revenue of $84.5-88.5 million, versus the consensus of $91.71 million. Guidewire Software sees FY2017 EPS of $0.69-$0.79, versus the consensus of $0.84. Guidewire Software sees FY2017 revenue of $471.5-483.5 million, versus the consensus of $475 million.
Sage Therapeutics (NASDAQ: SAGE) 5.7% LOWER; announced that it has commenced an underwritten public offering of $150.0 million of its common stock.
DAVIDsTEA Inc. (NASDAQ: DTEA) 5.1% LOWER; reported Q2 EPS of (CDN$0.09), CDN$0.02 worse than the analyst estimate of (CDN$0.07). Revenue for the quarter came in at CDN$41.1 million versus the consensus estimate of CDN$30.93 million. comparable sales increase of 5.1% GUIDANCE: DAVIDsTEA Inc. sees Q3 2016 EPS of (CDN$0.08)-(CDN$0.09). DAVIDsTEA Inc. sees Q3 2016 revenue of CDN$43-44 million. comparable sales increase in the low-single digit range.
Abeona Therapeutics (NASDAQ: ABEO) 4.4% HIGHER; Cantor Fitzgerald initiates coverage with a Buy rating and a price target of $21.00.
Healthcare Trust of America, Inc. (NYSE: HTA) 3.3% LOWER; announced that it has commenced an underwritten public offering of 3,500,000 shares of its common stock. In connection with the offering, HTA expects to grant the underwriters a 30-day option to purchase up to 525,000 additional shares of its common stock.
Bazaarvoice (NASDAQ: BV) 3% HIGHER; reported Q1 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $50.1 million versus the consensus estimate of $48.97 million.
Hewlett Packard Enterprise (NYSE: HPE) 1.4% LOWER; announced plans for a spin-off and merger of its non-core software assets with Micro Focus (LSE: MCRO) in a transaction valued at approximately $8.8 billion. In addition, HPE reported Q3 EPS of $0.49, $0.04 better than the analyst estimate of $0.45. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $12.64 billion. Hewlett Packard Enterprise sees FY2016 EPS of $1.90-$1.95, versus the consensus of $1.87.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- Cable ONE to Acquire NewWave Communications
- Cable ONE (CABO) to Acquire NewWave for $735M
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesCantor Fitzgerald, After-Hours Movers, Earnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!